Form D · Pharmaceuticals
GigaGen, Inc.
South San Francisco, CA · CIK 0001708610
Offering snapshot reported Jul 18, 2017 · SEC filing
- Reported sold
- $36.1M Offering amount: $36.1M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 3, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 18, 2017 | Initial | $36,126,542 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-290983
Source: Form D, filed Jul 18, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Johnson | Director, Executive |
| Carter Keller | Director |
| Chuck Wilson | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
407 Cabot Road
South San Francisco, CA, 94080
South San Francisco, CA, 94080